|
|
|
|
Education postcode lottery leading to complications
|
 |
|
Poor delivery of diabetes education is leading to devastating health complications for people with the condition and huge costs to the NHS, a group of cross-party MPs has warned.
Only 16 per cent of people newly diagnosed with diabetes are offered access to a formal course covering how to effectively manage their condition, according to a report published this month by the All-Party Parliamentary Group for Diabetes. To read more, click here.
|
|
|
'New approach needed' for inpatients with diabetes
|
 |
|
The NHS must take immediate action to raise standards of care in hospitals for people with diabetes, according to the UK’s leading specialist in diabetes inpatient care.
Dr Gerry Rayman, who is the lead for the National Diabetes Inpatient Audit, has advised that a new approach is needed to tackle the often poor care that people with diabetes receive in hospital and to address the almost 8-10 per cent higher mortality rate among inpatients with diabetes. To read more, click here.
|
|
|
National Type 2 diabetes prevention drived launched
|
 |
|
The NHS and Public Health in England will today start a major national initiative to prevent illness by unveiling the first ever at-scale National NHS Diabetes Prevention Programme.
Simon Stevens, NHS England’s Chief Executive, will announce the move in a major speech at the Diabetes UK conference in London. To read more, click here.
|
|
|
The Diabetes UK Professional Conference – Time to take control
|
 |
|
"After bouncing off stage I let out a huge sigh of relief. I looked around and saw faces staring at me, smiling at me, nodding and clapping… It was a very surreal moment, but one that will stay in my mind forever.”
I wrote this last year after delivering a presentation at the Diabetes UK Professional Conference about the Diabetes Online Community. I was able to provide an insight into what online support has to offer patients... To read more, click here.
|
|
|
Sanofi’s Toujeo® receives positive opinion from European regulatory authority
|
 |
|
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has announced a positive opinion recommending variation to the marketing authorisation of Toujeo (insulin glargine [rDNA origin] 300U/mL) for the treatment of adults with Type 1 and Type 2 diabetes in Europe. To read more, click here.
|
|
|
|
|
|
|
|
